Loading
A Dana-Farber study testing the Galleri blood test in people who carry an inherited gene change that raises their cancer risk.
INFORM (NCT06450171) is a single-arm interventional study sponsored by Dana-Farber Cancer Institute. Its primary outcome is the cancer detection rate.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,000 participants, a start on 27 September 2024 and primary completion expected on 31 January 2027.
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/